3/26
04:01 pm
zbio
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
High
Report
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
3/21
02:38 pm
zbio
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]
Medium
Report
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]
3/21
01:31 am
zbio
Medium
Report
3/19
06:20 am
zbio
Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
12:30 pm
zbio
Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.
3/17
08:01 am
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
3/17
08:01 am
zbio
Zenas BioPharma (ZBIO) had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an "equal weight" rating on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an "equal weight" rating on the stock.
3/17
04:47 am
zbio
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]
Low
Report
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]
3/16
09:04 pm
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
3/16
06:01 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/16
09:32 am
zbio
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/16
07:00 am
zbio
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/10
05:46 pm
zbio
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight [Yahoo! Finance]
Low
Report
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight [Yahoo! Finance]
2/28
11:22 am
zbio
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory [Yahoo! Finance]
Low
Report
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory [Yahoo! Finance]
2/21
02:04 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
2/20
04:15 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/17
10:46 am
zbio
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
Low
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
2/12
06:56 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
2/10
08:05 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
2/9
07:05 am
zbio
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Medium
Report
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
2/4
07:05 am
zbio
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2/3
01:54 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
1/29
10:00 am
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/27
01:22 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/22
10:00 am
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO